Skip to main content

Advertisement

Table 1 Clinical and pathological data of sporadic Alzheimer’s disease cases, Down syndrome cases, and nondemented control subjects

From: N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

     Aβ4–x (029-2) Aβ (IC16)
Case Age (years) Braak stage ApoE SP CAA SP CAA
Sporadic AD cases
 AD-1 87 V 3/3 ++ ++ +++ ++
 AD-2 83 VI 4/3 + + +++ +
 AD-3 78 V 4/3 ++ + +++ ++
 AD-4 79 IV 4/3 ++ +++ ++ +++
 AD-5 82 V 4/4 + + +++ ++
 AD-6 84 IV 4/3 ++ ++ +++ +++
 AD-7 85 VI 3/3 (+) − +++ ++
 AD-8 92 IV 3/3 + + ++ +
 AD-9 92 IV 4/2 + ++ +++ ++
 AD-10 73 IV 4/4 + ++ +++ +++
 AD-11 92 IV 3/3 ++ + +++ ++
 AD-12 93 IV 3/3 +++ (+) +++ (+)
 AD-13 81 IV n.d. ++ ++ +++ +++
 AD-14 95 IV 3/3 + − ++ −
 AD-15 91 IV 4/3 + + +++ +
 AD-16 65 VI 3/3 (+) − ++ −
 AD-17 79 V 3/3 + + ++ +
Nondemented control cases
 NDC-1 87 II n.d. − − − −
 NDC-2 90 I 2/2 + + ++ ++
 NDC-3 79 II 4/3 + − ++ −
 NDC-4 89 III n.d. − + − +
 NDC-5 78 I 3/3 − + (−) −
 NDC-6 82 I 3/3 − − − −
Down syndrome
 DS-1 64 V 3/3 ++ ++ +++ +++
 DS-2 58 VI 4/3 ++ +++ +++ +++
  1. Abbreviations: Aβ Amyloid-β, AD Alzheimer’s disease, ApoE Apolipoprotein E, CAA Cerebral amyloid angiopathy, DS Down syndrome, NDC Nondemented control subject, SP Senile plaques
  2. The following semiquantitative scoring criteria were used: − no staining, (+) barely detectable staining, + weak staining, ++ moderate staining, +++ extensive staining
Back to article page